Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is the leading cause of
death from an infectious disease globally. The widespread and ever-increasing resistance to …

Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant
(XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20 …

Improving treatment outcomes in multidrug‐resistant tuberculosis (MDR‐TB) is partly
hampered by inadequate effective antitubercular agents. Development of bedaquiline and …

This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

Introduction Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition
needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is …

Аннотация В статье представлены сведения о распространении туберкулеза с
МЛУ/РУ/ШЛУ в странах мира и регионах ВОЗ в сравнении с Российской Федерацией …

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …

Relatively little is known about the efficacy and safety of the programmatic use of
bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This …

Objectives We aimed to assess the effect of second-line anti-TB treatment and determine
which drugs can achieve the greatest clinical benefit for DR-TB-HIV patients by comparing …